Group | G1* | G2^{†} | P |
---|---|---|---|

Overall, LR positive (n) | 38 (17.3%) | 56 (25.5%) | 0.048 |

Overall, LR negative (n) | 145 (65.9%) | 137 (62.3%) | 0.487 |

Overall, LR equivocal (n) | 37 (16.8%) | 27 (12.3%) | 0.223 |

Median SUV_{max}, LR positive (n) | 8.1 (range, 3.2–47.9) | 8.4 (range, 3.2–139.0) | 0.987 |

Subgroup pRT, LR positive (n) | 12 (54.5%) | 20 (50.0%) | 0.795 |

Subgroup pRT, LR negative (n) | 8 (36.4%) | 15 (37.5%) | 1 |

Subgroup pRT, LR equivocal (n) | 2 (9.1%) | 5 (12.5%) | 1 |

Subgroup pRPE, LR positive (n) | 26 (13.1%) | 36 (20.0%) | 0.095 |

Subgroup pRPE, LR negative (n) | 137 (69.2%) | 126 (70.0%) | 0.911 |

Subgroup pRPE, LR equivocal (n) | 35 (17.7%) | 18.0 (10.0%) | 0.038 |

* No preparation.

† Injection of 20 mg of furosemide and 500 mL of NaCl 0.9%.

*P*values from Fisher exact tests for frequencies and from Mann–Whitney*U*test for median SUV_{max}comparison.pRPE = primary radical prostatectomy; pRT = primary radiation therapy; SUV

_{max}= maximal SUV.